Rice Hall James & Associates LLC raised its stake in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 31.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 669,560 shares of the biotechnology company’s stock after buying an additional 158,851 shares during the quarter. Rice Hall James & Associates LLC owned about 1.07% of Aimmune Therapeutics worth $13,940,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of AIMT. Legal & General Group Plc grew its position in shares of Aimmune Therapeutics by 29.1% in the 4th quarter. Legal & General Group Plc now owns 18,273 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 4,123 shares during the period. Botty Investors LLC acquired a new position in shares of Aimmune Therapeutics in the 1st quarter valued at approximately $2,505,000. Norges Bank acquired a new position in shares of Aimmune Therapeutics in the 4th quarter valued at approximately $6,035,000. DekaBank Deutsche Girozentrale grew its position in shares of Aimmune Therapeutics by 21.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 15,100 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 2,700 shares during the period. Finally, Pearl River Capital LLC acquired a new position in shares of Aimmune Therapeutics in the 1st quarter valued at approximately $28,000. Institutional investors own 75.85% of the company’s stock.
AIMT has been the subject of several research analyst reports. Royal Bank of Canada decreased their price objective on Aimmune Therapeutics to $50.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Roth Capital assumed coverage on Aimmune Therapeutics in a research report on Friday, July 12th. They issued a “buy” rating and a $45.00 price objective for the company. BidaskClub upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, ValuEngine upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. Aimmune Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $42.50.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.08). During the same period in the prior year, the company posted ($0.91) earnings per share. Analysts anticipate that Aimmune Therapeutics Inc will post -3.97 EPS for the current year.
Aimmune Therapeutics Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Further Reading: What is the Stochastic Momentum Index (SMI)?
Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.